Antiangiogene Therapie am vorderen Augenabschnitt

Bock, Felix; König, Yanyan; Dietrich, T.; Zimmermann, P.; Baier, Martin; Cursiefen, Claus

doi:10.1007/s00347-007-1512-2

Cited by 40 publications

(16 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bevacizumab is approved for the treatment of metastatic colorectal cancer. It is currently injected "offlabel" into the vitreous for the treatment of proliferative and nonproliferative diabetic retinopathy, neovascular agerelated macular degeneration, and neovascular glaucoma, with promising results [2].…”

Section: Introduction Backgroundmentioning

confidence: 99%

See 1 more Smart Citation

Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization

Koenig

Bock

Horn

et al. 2009

Graefes Arch Clin Exp Ophthalmol

166

116

View full text Add to dashboard Cite

Off-label topical bevacizumab therapy against corneal neovascularization secondary to different corneal diseases was generally well-tolerated for up to 12 months. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization, and lead to a reduction of the vessel diameter. Our results suggest that off-label use of Bevacizumab eye drops is a relatively safe and well-tolerated option for the treatment of corneal neovascularization. Care should be taken in patients with epithelial defects and neurotrophic keratopathy.

show abstract

Section: Introduction Backgroundmentioning

confidence: 99%

“…The human cornea is normally avascular, actively maintained by expression of antiangiogenic and antilymphangiogenic factors [1,2]. In various inflammatory, infectious, degenerative or traumatic disorders, corneal neovascularization may occur.…”

Section: Introduction Backgroundmentioning

confidence: 99%

Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization

Koenig

Bock

Horn

et al. 2009

Graefes Arch Clin Exp Ophthalmol

166

116

View full text Add to dashboard Cite

show abstract

“…5,81 In addition, studies have exhibited partial reduction of corneal neovascularization through topical, subconjunctival, and intraocular application of bevacizumab. 1,6,18,19,25,30,35,39,40,54–58,64,66,67,76,78,80,84,92,102,103,105,134,139,141 …”

Section: Introductionmentioning

confidence: 99%

Corneal Neovascularization: An Anti-VEGF Therapy Review

Chang

Garg

Lunde

et al. 2012

Survey of Ophthalmology

320

270

View full text Add to dashboard Cite

Corneal neovascularization is a serious condition that can lead to a profound decline in vision. The abnormal vessels block light, cause corneal scarring, compromise visual acuity, and may lead to inflammation and edema. Corneal neovascularization occurs when the balance between angiogenic and antiangiogenic factors is tipped toward angiogenic molecules. Vascular endothelial growth factor (VEGF), one of the most important mediators of angiogenesis, is upregulated during neovascularization. In fact, anti-VEGF agents have efficacy in the treatment of neovascular age-related macular degeneration, diabetic retinopathy, macular edema, neovascular glaucoma, and other neovascular diseases. These same agents have great potential for the treatment of corneal neovascularization. We review some of the most promising anti-VEGF therapies, including bevacizumab, VEGF trap, siRNA, and tyrosine kinase inhibitors.

show abstract

“…4 VEGF neutralizing agents have proven invaluable in the treatment of pathologic conditions such as neovascular age-related macular degeneration and diabetic retinopathy; furthermore, recent findings suggest that VEGF inhibition may be an effective therapeutic modality for corneal NV. 5-7 Because systemic anti-VEGF exposure is associated with severe and potentially life-threatening adverse events, it is prudent to pursue the route of administration that minimizes systemic exposure. 8 Herein, we present a brief review of corneal NV; additionally, we summarize our recent findings regarding the clinical utility of topical ranibizumab (Lucentis®; Genentech, Inc.; San Francisco, CA) and bevacizumab (Avastin®; Genentech, Inc.) in the treatment of corneal NV.…”

Section: Introductionmentioning

confidence: 99%

Corneal Neovascularization and the Utility of Topical VEGF Inhibition: Ranibizumab (Lucentis) Vs Bevacizumab (Avastin)

et al. 2012

View full text Add to dashboard Cite

Corneal avascularity is necessary for the preservation of optimal vision. The cornea maintains a dynamic balance between pro- and antiangiogenic factors that allows it to remain avascular under normal homeostatic conditions; however, corneal avascularity can be compromised by pathologic conditions that negate the cornea’s “angiogenic privilege.” The clinical relevance of corneal neovascularization has long been recognized, but management of this condition has been hindered by a lack of safe and effective therapeutic modalities. Herein, the etiology, epidemiology, pathogenesis, and treatment of corneal neovascularization are reviewed. Additionally, the authors’ recent findings regarding the clinical utility of topical ranibizumab (Lucentis®) and bevacizumab (Avastin®) in the treatment of corneal neovascularization are summarized. These findings clearly indicate that ranibizumab and bevacizumab are safe and effective treatments for corneal neovascularization when appropriate precautions are observed. Although direct comparisons are not conclusive, the results suggest that ranibizumab may be modestly superior to bevacizumab in terms of both onset of action and degree of efficacy. In order to justify the increased cost of ranibizumab, it will be necessary to demonstrate meaningful treatment superiority in a prospective, randomized, head-to-head comparison study.

show abstract

Antiangiogene Therapie am vorderen Augenabschnitt

Abstract: Novel antiangiogenic drugs are available for topical use in the anterior segment of the eye (as off-label use) and will improve the management of neovascular diseases affecting cornea and conjunctiva and in the anterior chamber of the eye.

Cited by 40 publications

References 33 publications

Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization

Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization

Corneal Neovascularization: An Anti-VEGF Therapy Review

Corneal Neovascularization and the Utility of Topical VEGF Inhibition: Ranibizumab (Lucentis) Vs Bevacizumab (Avastin)

Contact Info

Product

Resources

About